



Stratification of Outcomes for Lymphoma in Dogs (SOLID)

The Stratification of Outcomes for Lymphoma in Dogs (SOLID) study is a clinical trial focused on better understanding the genetics behind canine lymphoma. By studying changes in the DNA of these cancers, researchers hope to identify patterns that could lead to more personalized treatment options. The goal is to find markers in the tumor and blood that can help predict how the cancer will behave and guide more effective treatment decisions.

Canine lymphomas are a diverse group of cancers and are among the most common cancers diagnosed in dogs. Lymphoma is a type of cancer that stems from the lymphocytes which are a type of white blood cell that helps the immune system fight off infection. Canine lymphoma resembles non-Hodgkin's lymphoma in people. It is so similar, in fact, that veterinarians and human doctors use similar chemotherapy protocols to treat lymphoma in their patients.

WHO IS ELIGIBLE?

Dogs must have:

- Multicentric nodal lymphoma
- Enlarged lymph nodes suitable for biopsy
- No prior treatment (including steroids)
- Signed owner consent

STUDY PROCEDURES

About the SOLID Study:

Dogs diagnosed with multicentric nodal lymphoma, and no prior treatment (including corticosteroids) may be eligible for this study. Screening includes blood work, chest x-rays, lymph node biopsy, and a fine needle aspirate.

Eligible dogs will receive standard CHOP chemotherapy under the care of an Ethos Veterinary Health Oncologist.

A key part of the study involves collecting blood and tissue samples to study gene variants and biomarkers. These insights aim to improve prognosis and develop better treatment options for canine lymphoma.

WHAT IS INVOLVED?

- Blood samples will be taken before treatment begins, and at various points during and after chemotherapy.
- Only one lymph node biopsy (during initial screening) is required.
- Treatment and monitoring will continue until disease progression (relapse).
- After progression, dogs will be removed from the study but may continue care with their Oncologist.

CLIENT INCENTIVE

The study covers:

- Full cost of screening (bloodwork, urinalysis, chest x-rays, lymph node biopsy, flow cytometry)
- Routine bloodwork and urinalysis at set points during the study
- Up to \$6,000 in discounts for CHOP chemotherapy, exams, diagnostics, and medications for chemo-related side effects

Note: Total treatment costs may range from \$7,000 to over \$9,000. Any costs outside the study or unrelated to lymphoma treatment are the owner's responsibility.

ABOUT ETHOS DISCOVERY:

A 501(c)(3) nonprofit incubator of scientific innovation, Ethos Discovery's mission is to improve health outcomes for humans and animals with complex medical problems. Visit ethosdiscovery.org to learn more.

If you are interested in joining this study, feel free to reach us here!

Metropolitan Veterinary Hospital

- Akron: 330-670-2352
- Highland Heights: 216-201-9842

